



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed 

Dated 20 November 2003

THIS PAGE BLANK (USPTO)

Patents Form 1/77

Patents Act 1977
(Rule 16)

The Patent Office

23MAY01 E631486-1 000192
P01/7700 0.00-0112453.6

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form))



The Patent Office

Cardiff Road
Newport
Gwent NP10 8QQ

1. Your reference P.82642 JCI

2. Patent application number
(The Patent Office will fill in this part)

0112453.6

22 MAY 2001

3. Full name, address and postcode of the or of each applicant (underline all surnames)

PHARMA PACIFIC PTY. LTD.
103 - 105 Pipe Road
Laverton North
Victoria 3026
AUSTRALIA

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

07589484002
AUSTRALIA

4. Title of the invention INTERFERON - ALPHA INDUCED GENE

5. Name of your agent (if you have one) J A KEMP & CO

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

14 SOUTH SQUARE
GRAY'S INN
LONDON WC1R 5JJ

Patents ADP number (if you know it)

26001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer "Yes" if:

NO

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body:
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 29

Claim(s) 4

Abstract 1

Drawing(s) -

10. If you are also filing any of the following, state how many against each item.

Priority documents -

Translations of priority documents -

Statement of inventorship and right to grant of a patent (Patents Form 7/77) -

Request for preliminary examination and search (Patents Form 9/77) -

Request for substantive examination (Patents Form 10/77) -

Any other documents (please specify) -

11.

I/We request the grant of a patent on the basis of this application

Signature

J.A. Kemp - Co

J.A. KEMP & CO.

Date 22 May 2001

12. Name and daytime telephone number of person to contact in the United Kingdom

IRVINE, JONQUIL CLAIRE
020 7405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue of a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered "Yes" Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

INTERFERON-ALPHA INDUCED GENE

Field of the Invention

5 The present invention relates to identification of a human gene upregulated by interferon- α (IFN- α) administration, the coding sequence of which is believed to be previously unknown. Detection of expression products of this gene may find use in predicting responsiveness to IFN- α and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the isolated novel protein encoded by the same
10 gene is also envisaged.

Background of the Invention

IFN- α is widely used for the treatment of a number of disorders. Disorders
15 which may be treated using IFN- α include neoplastic diseases such as leukemia, lymphomas, and solid tumours, AIDS-related Kaposi's sarcoma and viral infections such as chronic hepatitis. IFN- α has also been proposed for administration via the oromucosal route for the treatment of autoimmune, mycobacterial, neurodegenerative, parasitic and
20 viral disease. In particular, IFN- α has been proposed, for example, for the treatment of multiple sclerosis, leprosy, tuberculosis, encephalitis, malaria, cervical cancer, genital herpes, hepatitis B and C, HIV, HPV and HSV-1 and 2. It has also been suggested for the treatment of arthritis, lupus and diabetes. Neoplastic diseases such as multiple myeloma, hairy cell leukemia, chronic myelogenous leukemia, low grade lymphoma, cutaneous T-cell lymphoma, carcinoid tumours, cervical cancer, sarcomas including Kaposi's
25 sarcoma, kidney tumours, carcinomas including renal cell carcinoma, hepatic cellular carcinoma, nasopharyngeal carcinoma, haematological malignancies, colorectal cancer, glioblastoma, laryngeal papillomas, lung cancer, colon cancer, malignant melanoma and brain tumours are also suggested as being treatable by administration of IFN- α via the oromucosal route, i.e. the oral route or the nasal route.

IFN- α is a member of the Type 1 interferon family, which exert their characteristic biological activities through interaction with the Type 1 interferon receptor. Other Type 1 interferons include IFN- β , IFN- ω and IFN- τ .

5 Unfortunately, not all potential patients for treatment with a Type 1 interferon such as interferon- α , particularly, for example, patients suffering from chronic viral hepatitis, neoplastic disease and relapsing remitting multiple sclerosis, respond
10 favourably to Type 1 interferon therapy and only a fraction of those who do respond exhibit long-term benefit. The inability of the physician to confidently predict the therapeutic outcome of Type 1 interferon treatment raises serious concerns as to the cost-benefit ratio of such treatment, not only in terms of wastage of an expensive
15 biopharmaceutical and lost time in therapy, but also in terms of the serious side effects to which the patient is exposed. Furthermore, abnormal production of IFN- α has been shown to be associated with a number of autoimmune diseases. For these reasons, there is much interest in identifying Type 1 interferon responsive genes since Type 1
interferons exert their therapeutic action by modulating the expression of a number of genes. Indeed, it is the specific pattern of gene expression induced by Type 1 interferon treatment that determines whether a patient will respond favourably or not to the
treatment.

20

Summary of the Invention

A human gene cDNA has now been identified as corresponding to a mouse gene
25 upregulated by administration of IFN- α by an oromucosal route or intraperitoneally and is believed to represent a novel DNA. The corresponding human gene is thus now also designated an IFN- α upregulated gene.

The protein encoded by the same gene is referred to below as HuIFRG 55.1
30 protein. This protein, and functional variants thereof, are now envisaged as therapeutic agents, in particular for use as an anti-viral, anti-tumour or immunomodulatory agent. For example, they may be used in the treatment of autoimmune, mycobacterial, neurodegenerative, parasitic or viral disease, arthritis, diabetes, lupus, multiple sclerosis,

leprosy, tuberculosis, encephalitis, malaria, cervical cancer, genital herpes, hepatitis B or C, HIV, HPV, HSV-1 or 2, or neoplastic disease such as multiple myeloma, hairy cell leukemia, chronic myelogenous leukemia, low grade lymphoma, cutaneous T-cell lymphoma, carcinoid tumours, cervical cancer, sarcomas including Kaposi's sarcoma, kidney tumours, carcinomas including renal cell carcinoma, hepatic cellular carcinoma, nasopharyngeal carcinoma, haematological malignancies, colorectal cancer, glioblastoma, laryngeal papillomas, lung cancer, colon cancer, malignant melanoma or brain tumours. In other words, such a protein may find use in treating any Type 1 interferon treatable disease.

Determination of the level of HuIFRG 55.1 protein or a naturally-occurring variant thereof, or the corresponding mRNA, in cell samples of Type 1 interferon-treated patients, e.g. patients treated with IFN- α , e.g. such as by the oromucosal route or intravenously, may also be used to predict responsiveness to such treatment. It has additionally been found that alternatively, and more preferably, such responsiveness may be judged, for example, by treating a sample of human peripheral blood mononuclear cells *in vitro* with a Type 1 interferon and looking for upregulation or downregulation of an expression product, preferably mRNA, corresponding to the HuIFRG 55.1 gene.

According to a first aspect of the invention, there is thus provided an isolated polypeptide comprising;

- (i) the amino acid sequence of SEQ ID NO: 2;
- (ii) a variant thereof having substantially similar function, e.g. an immunomodulatory activity and/or an anti-viral activity and/or an anti-tumour activity; or
- (iii) a fragment of (i) or (ii) which retains substantially similar function, e.g. an immunomodulatory activity and/or an anti-viral activity and/or an anti-tumour activity.

The invention also provides such a protein for use in therapeutic treatment of a human or non-human animal, more particularly for use as an anti-viral, anti-tumour or

immunomodulatory agent. As indicated above, such use may extend to any Type 1 interferon treatable disease.

According to another aspect of the invention, there is provided an isolated polynucleotide encoding a polypeptide of the invention as defined above or a complement thereof. Such a polynucleotide will typically include a sequence comprising:

- (a) the nucleic acid of SEQ. ID. No. 1 or the coding sequence thereof and/or a sequence complementary thereto;
- (b) a sequence which hybridises, e.g. under stringent conditions, to a sequence complementary to a sequence as defined in (a);
- (c) a sequence which is degenerate as a result of the genetic code to a sequence as defined in (a) or (b);
- (d) a sequence having at least 60% identity to a sequence as defined in (a), (b) or (c).

The invention also provides;

- an expression vector which comprises a polynucleotide of the invention and which is capable of expressing a polypeptide of the invention;
- a host cell containing an expression vector of the invention;
- an antibody specific for a polypeptide of the invention;
- a method of treating a subject having a Type 1 interferon treatable disease, which method comprises administering to the said patient an effective amount of HuIFRG 55.1 protein or a functional variant thereof
- use of such a polypeptide in the manufacture of a medicament for use in therapy as an anti-viral or anti-tumour or immunomodulatory agent, more particularly for use in treatment of a Type 1 interferon treatable disease;
- a pharmaceutical composition comprising a polypeptide of the invention and a pharmaceutically acceptable carrier or diluent;
- a method of producing a polypeptide of the invention, which method comprises maintaining host cells of the invention under conditions suitable for obtaining expression of the polypeptide and isolating the said polypeptide;

- a polynucleotide of the invention, e.g. in the form of an expression vector, which directs expression *in vivo* of a polypeptide as defined above for use in therapeutic treatment of a human or non-human animal, more particularly for use as an anti-viral, anti-tumour or immunomodulatory agent;
- a pharmaceutical composition comprising such a polynucleotide and a pharmaceutically acceptable carrier or diluent;
- a method of treating a subject having a Type 1 interferon treatable disease, which method comprises administering to said patient an effective amount of such a polynucleotide;
- use of such a polynucleotide in the manufacture of a medicament, e.g. a vector preparation, for use in therapy as an anti-viral, anti-tumour or immunomodulatory agent, more particularly for use in treating a Type 1 interferon treatable disease; and
- a method of identifying a compound having immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity comprising providing a cell capable of expressing HuIFRG 55.1 protein or a naturally occurring variant thereof, incubating said cell with a compound under test and monitoring for upregulation of HuIFRG 55.1 gene expression.

In a still further aspect, the invention provides a method of predicting responsiveness of a patient to treatment with a Type 1 interferon, e.g. IFN- α treatment (such as IFN- α treatment by the oromucosal route or a parenteral route, for example, intravenously, subcutaneously, or intramuscularly), which comprises determining the level of HuIFRG 55.1 protein or a naturally-occurring variant thereof, e.g. an allelic variant, or the corresponding mRNA, in a cell sample from said patient, e.g. a blood sample, wherein said sample is obtained from said patient following administration of a Type 1 interferon, e.g. IFN- α by an oromucosal route or intravenously, or is treated prior to said determining with a Type 1 interferon such as IFN- α *in vitro*. The invention also extends to kits for carrying out such testing.

Brief description of the Sequences

SEQ. ID. No.1 is the amino acid sequence of human protein HuIFRG 55.1 and its encoding cDNA.

5 SEQ. ID. No.2 is the amino acid sequence alone of HuIFRG 55.1 protein.

Detailed Description of the Invention

10 As indicated above, human protein HuIFRG 55.1 and functional variants thereof are now envisaged as therapeutically useful agents, more particularly for use as an anti-viral, anti-tumour or immunomodulatory agent.

A variant of HuIFRG 55.1 protein for this purpose may be a naturally occurring
15 variant, either an allelic variant or species variant, which has substantially the same functional activity as HuIFRG 55.1 protein and is also upregulated in response to administration of IFN- α . Alternatively, a variant of HuIFRG 55.1 protein for therapeutic use may comprise a sequence which varies from SEQ. ID. No. 2 but which is a non-natural mutant.

20

The term " functional variant" refers to a polypeptide which has the same essential character or basic function of HuIFRG 55.1 protein. The essential character of HuIFRG 55.1 protein may be deemed to be as an immunomodulatory peptide. A functional variant polypeptide may show additionally or alternatively anti-viral activity
25 and/or anti-tumour activity.

Desired anti-viral activity may, for example, be tested or monitored as follows. A sequence encoding a variant to be tested is cloned into a retroviral vector such as a retroviral vector derived from the Moloney murine leukemia virus (MoMuLV)
30 containing the viral packaging signal ψ , and a drug-resistance marker. A pantropic packaging cell line containing the viral *gag*, and *pol*, genes is then co-transfected with the recombinant retroviral vector and a plasmid, pVSV-G, containing the vesicular stomatitis virus envelope glycoprotein in order to produce high-titre infectious replication incompetent virus (Burns *et al.*, Proc. Natl. Acad. Sci. USA **84**, 5232-5236).

The infectious recombinant virus is then used to transfect interferon sensitive fibroblasts or lymphoblastoid cells and cell lines that stably express the variant protein are then selected and tested for resistance to virus infection in a standard interferon bio-assay (Tovey *et al.*, Nature, **271**, 622-625, 1978). Growth inhibition using a standard proliferation assay (Mosmann, T., J. Immunol. Methods, **65**, 55-63, 1983) and expression of MHC class I and class II antigens using standard techniques may also be determined.

A desired functional variant of HuIFRG 55.1 may consist essentially of the sequence of SEQ. ID. No. 2. A functional variant of SEQ. ID. No.2 may be a polypeptide which has a least 60% to 70% identity, preferably at least 80% or at least 90% and particularly preferably at least 95%, at least 97% or at least 99% identity with the amino acid sequence of SEQ. ID. No. 2 over a region of at least 20, preferably at least 30, for instance at least 100 contiguous amino acids or over the full length of SEQ. ID. No. 2. Methods of measuring protein identity are well known in the art.

Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions. Conservative substitutions may be made, for example according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other.

ALIPHATIC	Non-polar	G A P
		I L V
	Polar-uncharged	C S T M
		N Q
	Polar-charged	D E
		K R
AROMATIC		H F W Y

Variant polypeptide sequences for therapeutic use in accordance with the invention may be shorter polypeptide sequences, for example, a peptide of at least 20

amino acids or up to 50, 60, 70, 80, 100, 150 or 200 amino acids in length is considered to fall within the scope of the invention provided it retains appropriate biological activity of HuIFRG 55.1 protein. In particular, but not exclusively, this aspect of the invention encompasses the situation when the variant is a fragment of a complete natural naturally-
5 occurring protein sequence.

Also encompassed by the invention are modified forms of HuIFRG 55.1 protein and fragments thereof which can be used to raise anti-HuIFRG 55.1 protein antibodies. Such variants will comprise an epitope of the HuIFRG 55.1 protein.

10 Polypeptides of the invention may be chemically modified, e.g. post-translationally modified. For example, they may be glycosylated and/or comprise modified amino acid residues. They may also be modified by the addition of a sequence at the N-terminus and/or C-terminus, for example by provision of histidine residues or a
15 T7 tag to assist their purification or by the addition of a signal sequence to promote insertion into the cell membrane. Such modified polypeptides fall within the scope of the term "polypeptide" of the invention.

A polypeptide of the invention may be labelled with a revealing label. The
20 revealing label may be any suitable label which allows the polypeptide to be detected. Suitable labels include radioisotopes such as ^{125}I , ^{35}S or enzymes, antibodies, polynucleotides and linkers such as biotin. Labelled polypeptides of the invention may be used in assays. In such assays it may be preferred to provide the polypeptide attached to a solid support. The present invention also relates to such labelled and/or immobilised
25 polypeptides packaged in the form of a kit in a container. The kit may optionally contain other suitable reagent(s), control(s) or instructions and the like.

The polypeptides of the invention may be made synthetically or by recombinant means. Such polypeptides of the invention may be modified to include non-naturally
30 occurring amino acids, e.g. D amino acids. Variant polypeptides of the invention may have modifications to increase stability *in vitro* and/or *in vivo*. When the polypeptides are produced by synthetic means, such modifications may be introduced during production.

The polypeptides may also be modified following either synthetic or recombinant production.

5 A number of side chain modifications are known in the protein modification art and may be present in polypeptides of the invention. Such modifications include, for example, modifications of amino acids by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 , amidination with methylacetimidate or acylation with acetic anhydride.

10 Polypeptides of the invention will be in substantially isolated form. It will be understood that the polypeptides may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated. A polypeptide of the invention may also be in substantially purified form, in which case it will generally comprise the polypeptide in a preparation in
15 which more than 90%, for example more than 95%, 98% or 99%, by weight of polypeptide in the preparation is a polypeptide of the invention.

Polynucleotides

20 The invention also includes isolated nucleotide sequences that encode HuIFRG 55.1 protein or a variant thereof as well as isolated nucleotide sequences which are complementary thereto. The nucleotide sequence may be DNA or RNA, single or double stranded, including genomic DNA, synthetic DNA or cDNA. Preferably the nucleotide sequence is a DNA sequence and most preferably, a cDNA sequence.

25

As indicated above, such a polynucleotide will typically include a sequence comprising:

- (a) the nucleic acid of SEQ. ID. No. 1 or the coding sequence thereof and/or a sequence complementary thereto;
- 30 (b) a sequence which hybridises, e.g. under stringent conditions, to a sequence complementary to a sequence as defined in (a);
- (c) a sequence which is degenerate as a result of the genetic code to a sequence as defined in (a) or (b);

- (d) a sequence having at least 60% identity to a sequence as defined in (a), (b) or (c).

Polynucleotides comprising an appropriate coding sequence can be isolated from human cells or synthesised according to methods well known in the art, as described by way of example in Sambrook *et al.* (1989) Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press.

Polynucleotides of the invention may include within them synthetic or modified nucleotides. A number of different types of modification to polynucleotides are known in the art. These include methylphosphonate and phosphothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. Such modifications may be carried out in order to enhance the *in vivo* activity or lifespan of polynucleotides of the invention.

Typically a polynucleotide of the invention will include a sequence of nucleotides, which may preferably be a contiguous sequence of nucleotides, which is capable of hybridising under selective conditions to the coding sequence or the complement of the coding sequence of SEQ. ID. No. 1. Such hybridisation will occur at a level significantly above background. Background hybridisation may occur, for example, because of other cDNAs present in a cDNA library. The signal level generated by the interaction between a polynucleotide of the invention and the coding sequence or complement of the coding sequence of SEQ. ID. No. 1 will typically be at least 10 fold, preferably at least 100 fold, as intense as interactions between other polynucleotides and the coding sequence of SEQ. ID. No. 1. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with ³²P. Selective hybridisation may typically be achieved using conditions of low stringency (0.3M sodium chloride and 0.03M sodium citrate at about 40°C), medium stringency (for example, 0.3M sodium chloride and 0.03M sodium citrate at about 50°C) or high stringency (for example, 0.03M sodium chloride and 0.03M sodium citrate at about 60°C).

The coding sequence of SEQ ID No: 1 may be modified by nucleotide substitutions, for example from 1, 2 or 3 to 10, 25, 50 or 100 substitutions. Degenerate substitutions may be made and/or substitutions may be made which would result in a conservative amino acid substitution when the modified sequence is translated, for example as shown in the table above. The coding sequence of SEQ. ID. NO: 1 may alternatively or additionally be modified by one or more insertions and/or deletions and/or by an extension at either or both ends.

A polynucleotide of the invention capable of selectively hybridising to a DNA sequence selected from SEQ. ID No.1, the coding sequence thereof and DNA sequences complementary thereto will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% or 97%, homologous to the target sequence. This homology may typically be over a region of at least 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous nucleotides.

15

Any combination of the above mentioned degrees of homology and minimum sized may be used to define polynucleotides of the invention, with the more stringent combinations (i.e. higher homology over longer lengths) being preferred. Thus for example a polynucleotide which is at least 80% homologous over 25, preferably over 30 nucleotides forms may be found suitable, as may be a polynucleotide which is at least 90% homologous over 40 nucleotides.

Homologues of polynucleotide or protein sequences as referred to herein may be determined in accordance with well-known means of homology calculation, e.g. protein homology may be calculated on the basis of amino acid identity (sometimes referred to as "hard homology"). For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology, for example used on its default settings, (Devereux *et al.* (1984) *Nucleic Acids Research* **12**, 387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences or to identify equivalent or corresponding sequences, typically used on their default settings, for example as described in Altschul S. F. (1993) *J. Mol. Evol.* **36**,290-300; Altschul, S. F. *et al.* (1990) *J. Mol. Biol.* **215**,403-10.

Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul *et al.*, supra). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA **89**,10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

Polynucleotides according to the invention have utility in production of the proteins according to the invention, which may take place *in vitro*, *in vivo* or *ex vivo*. In such a polynucleotide, the coding sequence for the desired protein of the invention will

be operably-linked to a promoter sequence which is capable of directing expression of the desired protein in the chosen host cell. Such a polynucleotide will generally be in the form of an expression vector. Polynucleotides of the invention, e.g. in the form of an expression vector, which direct expression *in vivo* of a polypeptide of the invention having immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity may also be used as a therapeutic agent.

Expression vectors for such purposes may be constructed in accordance with conventional practices in the art of recombinant DNA technology. They may, for example, involve the use of plasmid DNA. They may be provided with an origin of replication. Such a vector may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid. Other features of vectors of the invention may include appropriate initiators, enhancers and other elements, such as for example polyadenylation signals which may be desirable, and which are positioned in the correct orientation, in order to allow for protein expression. Other suitable non-plasmid vectors would be apparent to persons skilled in the art. By way of further example in this regard reference is made again to Sambrook *et al.*, 1989 (*supra*). Such vectors additionally include, for example, viral vectors. Examples of suitable viral vectors include herpes simplex viral vectors, replication-defective retroviruses, including lentiviruses, adenoviruses, adeno-associated virus, HPV viruses (such as HPV-16 and HPV-18) and attenuated influenza virus vectors.

Promoters and other expression regulation signals may be selected to be compatible with the host cell for which expression is designed. For example, yeast promoters include *S. cerevisiae* GAL4 and ADH promoters, *S. pombe* *nmt1* and *adh* promoter. Mammalian promoters include the metallothionein promoter which can be induced in response to heavy metals such as cadmium and β -actin promoters. Viral promoters such as the SV40 large T antigen promoter or adenovirus promoters may also be used. Other examples of viral promoters which may be employed include the Moloney murine leukemia virus long terminal repeat (MMLV LTR), the rous sarcoma virus (RSV) LTR promoter, the human cytomegalovirus (CMV) IE promoter, and HPV

promoters, particularly the HPV upstream regulatory region (URR). Other suitable promoters will be well-known to those skilled in the recombinant DNA art.

5 An expression vector of the invention may further include sequences flanking the coding sequence for the desired polypeptide of the invention providing sequences homologous to eukaryotic genomic sequences, preferably mammalian genomic sequences, or viral genomic sequences. This will allow the introduction of such polynucleotides of the invention into the genome of eukaryotic cells or viruses by homologous recombination. In particular, a plasmid vector comprising the expression
10 cassette flanked by viral sequences can be used to prepare a viral vector suitable for delivering the polynucleotides of the invention to a mammalian cell.

The invention also includes cells *in vitro*, for example prokaryotic or eukaryotic cells, which have been modified to express the HuIFRG 55.1 protein or a variant thereof.
15 Such cells include stable, e.g. eukaryotic, cell lines wherein a polynucleotide encoding HuIFRG 55.1 protein or a variant thereof is incorporated into the host genome. Host cells of the invention may be mammalian cells or insect cells, lower eukaryotic cells, such as yeast or prokaryotic cells such as bacterial cells. Particular examples of cells which may be modified by insertion of vectors encoding for a polypeptide according to the invention
20 include mammalian HEK293T, CHO, HeLa and COS cells. Preferably a cell line may be chosen which is not only stable, but also allows for mature glycosylation of a polypeptide. Expression may, for example, be achieved in transformed oocytes.

A polypeptide of the invention may be expressed in cells of a transgenic non-
25 human animal, preferably a mouse. A transgenic non-human animal capable of expressing a polypeptide of the invention is included within the scope of the invention.

Polynucleotides according to the invention may also be inserted into vectors as described above in an antisense orientation in order to provide for the production of
30 antisense sequences. Antisense RNA or other antisense polynucleotides may also be produced by synthetic means.

A polynucleotide, e.g. in the form of an expression vector, capable of expressing *in vivo* an antisense sequence to a coding sequence for the amino acid sequence defined by SEQ. ID. No. 2, or a naturally-occurring variant thereof, for use in therapeutic treatment of a human or non-human animal is also envisaged as constituting an additional aspect of the invention. Such a polynucleotide will find use in treatment of diseases associated with upregulation of HuIFRG 55.1 protein.

Polynucleotides of the invention extend to sets of primers for nucleic acid amplification which target sequences within the cDNA for a polypeptide of the invention, e.g. pairs of primers for PCR amplification. The invention also provides probes suitable for targeting a sequence within a cDNA or RNA for a polypeptide of the invention which may be labelled with a revealing label, e.g. a radioactive label or a non-radioactive label such as an enzyme or biotin. Such probes may be attached to a solid support. Such a solid support may be a micro-array (also commonly referred to as nucleic acid, probe or DNA chip) carrying probes for further nucleic acids, e.g. mRNAs or amplification products thereof corresponding to other Type 1 interferon upregulated genes, e.g. such genes identified as upregulated in response to oromucosal or intravenous administration of IFN- α . Methods for constructing such micro-arrays are well-known (see, for example, EP-B 0476014 and 0619321 of Affymax Technologies N.V. and Nature Genetics Supplement January 1999 entitled "The Chipping Forecast").

The nucleic acid sequence of such a primer or probe will preferably be at least 10, preferably at least 15 or at least 20, for example at least 25, at least 30 or at least 40 nucleotides in length. It may, however, be up to 40, 50, 60, 70, 100 or 150 nucleotides in length or even longer.

Another aspect of the invention is the use of probes or primers of the invention to identify mutations in HuIFRG 55.1 genes, for example single nucleotide polymorphisms (SNPs).

As indicated above, in a still further aspect the present invention provides a method of identifying a compound having immunomodulatory activity and/or antiviral activity and/or anti-tumour activity comprising providing a cell capable of expressing

(HuIFRG 55.1 protein or a naturally-occurring variant thereof, incubating said cell with a compound under test and monitoring for upregulation of HuIFRG 55.1 gene expression. Such monitoring may be by probing for mRNA encoding HuIFRG 55.1 protein or a naturally-occurring variant thereof. Alternatively antibodies or antibody fragments
5 capable of specifically binding one or more of HuIFRG 55.1 and naturally-occurring variants thereof may be employed.

Antibodies

10 According to another aspect, the present invention also relates to antibodies (for example polyclonal or preferably monoclonal antibodies, chimeric antibodies, humanised antibodies and fragments thereof which retain antigen-binding capability) which have been obtained by conventional techniques and are specific for a polypeptide of the invention. Such antibodies could, for example, be useful in purification, isolation
15 or screening methods involving immunoprecipitation and may be used as tools to further elucidate the function of HuIFRG 55.1 protein or a variant thereof. They may be therapeutic agents in their own right. Such antibodies may be raised against specific epitopes of proteins according to the invention. An antibody specifically binds to a protein when it binds with high affinity to the protein for which it is specific but does not
20 bind or binds with only low affinity to other proteins. A variety of protocols for competitive binding or immunoradiometric assays to determine the specific binding capability of an antibody are well-known.

Pharmaceutical compositions

25 A polypeptide of the invention is typically formulated for administration with a pharmaceutically acceptable carrier or diluent. The pharmaceutical carrier or diluent may be, for example, an isotonic solution. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose,
30 corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methyl cellulose, carboxymethylcellulose or polyvinyl pyrrolidone; desegregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate;

effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, 5 tableting, sugar-coating, or film coating processes.

Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

10

Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methyl cellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive 15 oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

Solutions for intravenous administration or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic 20 saline solutions.

A suitable dose of HuIFRG 55.1 protein or a functional analogue thereof for use in accordance with the invention may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to 25 be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular patient. A typical daily dose may be from about 0.1 to 50 mg per kg, preferably from about 0.1mg/kg to 10mg/kg of body weight, according to the activity of the specific inhibitor, the age, weight and condition of the subject to be treated, and the frequency 30 and route of administration. Preferably, daily dosage levels may be from 5 mg to 2 g.

A polynucleotide of the invention suitable for therapeutic use will also typically be formulated for administration with a pharmaceutically acceptable carrier or diluent. Such a polynucleotide may be administered by any known technique whereby expression of the desired polypeptide can be attained *in vivo*. For example, the polynucleotide may be introduced by injection, preferably intradermally, subcutaneously or intramuscularly. Alternatively, the nucleic acid may be delivered directly across the skin using a particle-mediated delivery device. A polynucleotide of the invention suitable for therapeutic nucleic acid may alternatively be administered to the oromucosal surface for example by intranasal or oral administration.

A non-viral vector of the invention suitable for therapeutic use may, for example, be packaged into liposomes or into surfactant containing vector delivery particles. Uptake of nucleic acid constructs of the invention may be enhanced by several known transfection techniques, for example those including the use of transfection agents. Examples of these agents include cationic agents, for example calcium phosphate and DEAE dextran and lipofectants, for example lipopfectam and transfectam. The dosage of the nucleic acid to be administered can be varied. Typically, the nucleic acid will be administered in the range of from 1pg to 1mg, preferably from 1pg to 10 μ g nucleic acid for particle-mediated gene delivery and from 10 μ g to 1 mg for other routes.

Prediction of Type 1 interferon responsiveness

As also indicated above, in a still further aspect the present invention provides a method of predicting responsiveness of a patient to treatment with a Type 1 interferon, e.g. IFN- α treatment such as IFN- α treatment by an oromucosal route or intravenously, which comprises determining the level of HuIFRG 55.1 protein or a naturally-occurring variant thereof, or the corresponding mRNA, in a cell sample from said patient, wherein said sample is taken from said patient following administration of a Type 1 interferon or is treated prior to said determining with a Type 1 interferon *in vitro*.

Preferably, the Type 1 interferon for testing responsiveness will be the Type 1 interferon selected for treatment. It may be administered by the proposed treatment route

and at the proposed treatment dose. Preferably, the subsequent sample analysed may be, for example, a blood sample or a sample of peripheral blood mononuclear cells (PBMCs) isolated from a blood sample.

5 More conveniently and preferably, a sample obtained from the patient comprising PBMCs isolated from blood may be treated *in vitro* with a Type 1 interferon, e.g. at a dosage range of about 1 to 10,000 IU/ml. Such treatment may be for a period of hours, e.g. about 7 to 8 hours. Preferred treatment conditions for such *in vitro* testing may be determined by testing PBMCs taken from normal donors with the same interferon and
10 looking for upregulation of an appropriate expression product. Again, the Type 1 interferon employed will preferably be the Type 1 interferon proposed for treatment of the patient, e.g. recombinant IFN- α . PBMCs for such testing may be isolated in conventional manner from a blood sample using Ficoll-Hypaque density gradients. An example of a suitable protocol for such *in vitro* testing of Type 1 interferon
15 responsiveness is provided in Example 3 below.

The sample, if appropriate after *in vitro* treatment with a Type 1 interferon, may be analysed for the level of HuIFRG 55.1 protein or a naturally-occurring variant thereof. This may be done using an antibody or antibodies capable of specifically binding one or
20 more of HuIFRG 55.1 protein and naturally-occurring variants thereof, e.g. allelic variants thereof. Preferably, however, the sample will be analysed for mRNA encoding HuIFRG 55.1 protein or a naturally-occurring variant thereof. Such mRNA analysis may employ any of the techniques known for detection of mRNAs, e.g. Northern blot detection or mRNA differential display. A variety of known nucleic acid amplification
25 protocols may be employed to amplify any mRNA of interest present in the sample, or a portion thereof, prior to detection. The mRNA of interest, or a corresponding amplified nucleic acid, may be probed for using a nucleic acid probe attached to a solid support. Such a solid support may be a micro-array as previously discussed above carrying probes to determine the level of further mRNAs or amplification products thereof corresponding
30 to Type 1 interferon upregulated genes, e.g. such genes identified as upregulated in response to oromucosal or intravenous administration of IFN- α .

The following examples illustrate the invention:

Examples

5 Example 1

Previous experiments had shown that the application of 5 μ l of crystal violet to each nostril of a normal adult mouse using a P20 Eppendorf micropipette resulted in an almost immediate distribution of the dye over the whole surface of the oropharyngeal cavity. Staining of the oropharyngeal cavity was still apparent some 30 minutes after application of the dye. These results were confirmed by using 125 I-labelled recombinant human IFN- α 1-8 applied in the same manner. The same method of administration was employed to effect oromucosal administration in the studies which are described below.

15 Six week old, male DBA/2 mice were treated with either 100,000 IU of recombinant murine interferon α (IFN α) purchased from Life Technologies Inc, in phosphate buffered saline (PBS), 10 μ g of recombinant human interleukin 15 (IL-15) purchased from Protein Institute Inc, PBS containing 100 μ g/ml of bovine serum albumin (BSA), or left untreated. Eight hours later, the mice were sacrificed by cervical dislocation and the lymphoid tissue was removed surgically from the oropharyngeal cavity and snap frozen in liquid nitrogen and stored at -80°C. RNA was extracted from the lymphoid tissue by the method of Chomczynski and Sacchi 1987, (Anal. Biochem. 162, 156-159) and subjected to mRNA Differential Display Analysis (Lang, P. and 20 Pardee, A.B., Science, 257, 967-971).

Differential Display Analysis

Differential display analysis was carried out using the "Message Clean" and "RNA image" kits of the GenHunter Corporation essentially as described by the manufacturer. Briefly, RNA was treated with RNase-free DNase, and 1 μ g was reverse-transcribed in 100 μ l of reaction buffer using either one or the other of the three one-base anchored oligo-(dT) primers A, C, or G. RNA was also reverse-transcribed using one or the other of the 9 two-base anchored oligo-(dT) primers AA, CC, GG, AC, CA, GA, AG, CG, GC. All the 35 samples to be compared were reverse transcribed in the same experiment, separated into

aliquots and frozen. The amplification was performed with only 1 µl of the reverse transcription sample in 10 µl of amplification mixture containing *Taq* DNA polymerase and α -³³P dATP (3,000 Ci/mmol). Eighty 5' end (HAP) random sequence primers were used in combination with each of the (HT11) A, C, G, AA, CC, GG, AC, CA, GA, AG, CG or GC primers. Samples were then run on 7% denaturing polyacrylamide gels and exposed to autoradiography. Putative differentially expressed bands were cut out, reamplified according to the instructions of the supplier, and further used as probes to hybridize Northern blots of RNA extracted from the oropharyngeal cavity of IFN treated, IL-15 treated, and excipient treated animals.

Cloning and Sequencing

Re-amplified bands from the differential display screen were cloned in the *Sfr* 1 site of the pPCR-Script SK(+) plasmid (Stratagene) and cDNAs amplified from the rapid amplification of cDNA ends were isolated by TA cloning in the pCR3 plasmid (Invitrogen). DNA was sequenced using an automatic di-deoxy sequencer (Perkin Elmer ABI PRISM 377).

Isolation of Human cDNA

Differentially expressed murine 3' sequences identified from the differential display screen were compared with random human expressed sequence tags (EST) present in the dbEST database of GenBank™ of the United States National Center for Biotechnology Information (NCBI). The sequences potentially related to the murine EST isolated from the differential display screen were combined in a contig and used to construct a human consensus sequence corresponding to a putative cDNA. One such cDNA was found to be 1865 nucleotides in length. This corresponded to a mouse gene whose expression was found to be enhanced approximately 2-fold in the lymphoid tissue of the oral cavity of mice following oromucosal administration of IFN- α .

In order to establish that this putative cDNA corresponded to an authentic human gene, primers derived from the 5' and 3' ends of the consensus sequence were used to synthesise cDNA from mRNA extracted from human peripheral blood leukocytes (PBL)

by specific reverse transcription and PCR amplification. A unique cDNA fragment of the predicted size was obtained, cloned and sequenced (SEQ. ID. No.1). This human cDNA contains an open reading frame (ORF) of 1473 bp in length at positions 111-1583 encoding a protein of 490 amino acids (SEQ. ID. No. 2).

Example 2

Intravenous administration of IFN- α

Male DBA/2 mice were injected intraperitoneally with 100,000 IU of recombinant murine IFN- α purchased from Life Technologies Inc. in 200 μ l of PBS or treated with an equal volume of PBS alone. Eight hours later, the animals were sacrificed by cervical dislocation and the spleen was removed using conventional procedures. Total RNA was extracted by the method of Chomczynski and Sacchi (Anal. Biochem. (1987) 162,156-159) and 10.0 μ g of total RNA per sample was subjected to Northern blotting in the presence of glyoxal and hybridised with a cDNA probe for HuIFRG 55.1 mRNA as described by Dandoy-Dron et al.(J. Biol. Chem. (1998) 273, 7691-7697). The blots were first exposed to autoradiography and then quantified using a PhosphorImager according to the manufacturer's instructions. Enhanced levels of mRNA for HuIFRG 55.1 protein (approximately 4 fold) were detected in samples of RNA extracted from spleens of IFN- α treated animals relative to animals treated with excipient alone.

Example 3

Testing Type 1 interferon responsiveness *in vitro*

Human Daudi or HeLa cells were treated *in vitro* with 10,000 IU of recombinant human IFN- α 2 (Intron A from Schering-Plough) in PBS or with an equal volume of PBS alone. Eight hours later the cells were centrifuged (800 x g for 10 minutes) and the cell pellet recovered. Total RNA was extracted from the cell pellet by the method of Chomczynski and Sacchi and 10.0 μ g of total RNA per sample was subjected to Northern blotting in the presence of glyoxal and hybridised with a cDNA probe for

(HuIFRG 55.1 mRNA as previously described in Example 2 above. Enhanced levels of mRNA for HUIFRG 55.1 protein (approximately 2-fold) were detected in samples of RNA extracted from IFN- α treated Daudi or HeLa cells compared to samples treated with PBS alone.

5

The same procedure may be used to predict Type 1 interferon responsiveness using PBMCs taken from a patient proposed to be treated with a Type 1 interferon.

10

SEQUENCE LISTING

<110> PHARMA PACIFIC PTY LTD

5 <120> INTERFERON-ALPHA INDUCED GENE

<130> P.82642 JCI

<160> 2

10 <170> PatentIn version 3.0

<210> 1

<211> 1865

15 <212> DNA

<213> Homo sapiens

<220>

<221> CDS

20 <222> (111)..(1583)

<400> 1

cggagtcaca gttcccgag gcggcgacag cagagcgccc actgcctcca gcagattaat 60

25 attaagattg gaagtttgtg tcttttgctg gatattggaa attgaatgta atg gca 116
Met Ala
1

30 aca gaa ttt ata aag agt tgc tgt gga gga tgt ttc tat ggt gaa aca 164
Thr Glu Phe Ile Lys Ser Cys Cys Gly Gly Cys Phe Tyr Gly Glu Thr
5 10 15

35 gaa aaa cac aac ttt tct gtg gaa aga gat ttt aaa gca gca gtc cca 212
Glu Lys His Asn Phe Ser Val Glu Arg Asp Phe Lys Ala Ala Val Pro
20 25 30

40 aat agt caa aat gct act atc tct gta cct cca ttg act tct gtt tct 260
Asn Ser Gln Asn Ala Thr Ile Ser Val Pro Pro Leu Thr Ser Val Ser
35 40 45 50

45 gta aag cct cag ctt ggc tgt act gag gat tat ttg ctt tcc aaa tta 308
Val Lys Pro Gln Leu Gly Cys Thr Glu Asp Tyr Leu Leu Ser Lys Leu
55 60 65

50 cca tct gat ggc aaa gaa gta cca ttt gtg gtg ccc aag ttt aag tta 356
Pro Ser Asp Gly Lys Glu Val Pro Phe Val Val Pro Lys Phe Lys Leu
70 75 80

tct tac att caa ccc agg aca caa gaa act cct tca cat ctg gaa gaa 404
Ser Tyr Ile Gln Pro Arg Thr Gln Glu Thr Pro Ser His Leu Glu Glu
85 90 95

	ctt gaa gga tct gcc aga gca tct ttt gga gat cga aag gta gaa ctt Leu Glu Gly Ser Ala Arg Ala Ser Phe Gly Asp Arg Lys Val Glu Leu 100 105 110	452
5	tcc agt tca tcc cag cac gga cct agc tat gat gtg tat aac cca ttc Ser Ser Ser Ser Gln His Gly Pro Ser Tyr Asp Val Tyr Asn Pro Phe 115 120 125 130	500
10	tat atg tat cag cac att tca cct gat ttg agt cga cgc ttt cct ccc Tyr Met Tyr Gln His Ile Ser Pro Asp Leu Ser Arg Arg Phe Pro Pro 135 140 145	548
15	cgt tca gaa gtg acg aga ctg tat gga tcg gtt tgt gat tta agg acg Arg Ser Glu Val Thr Arg Leu Tyr Gly Ser Val Cys Asp Leu Arg Thr 150 155 160	596
20	aac aaa ctt ccc ggt tcc cct ggg cta agc aaa tct atg ttt gat ctt Asn Lys Leu Pro Gly Ser Pro Gly Leu Ser Lys Ser Met Phe Asp Leu 165 170 175	644
	aca aac tca tct cag cga ttc atc cag aga cat gat tca ttg tcc agt Thr Asn Ser Ser Gln Arg Phe Ile Gln Arg His Asp Ser Leu Ser Ser 180 185 190	692
25	gta ccc agt agt tct tct tca agg aaa aat tct cag ggg agt aac aga Val Pro Ser Ser Ser Ser Ser Arg Lys Asn Ser Gln Gly Ser Asn Arg 195 200 205 210	740
30	agc ctg gat aca att act cta tca gga gat gaa agg gac ttt ggg aga Ser Leu Asp Thr Ile Thr Leu Ser Gly Asp Glu Arg Asp Phe Gly Arg 215 220 225	788
35	ctg aat gtg aaa ttg ttt tat aat tct tca gta gaa cag atc tgg atc Leu Asn Val Lys Leu Phe Tyr Asn Ser Ser Val Glu Gln Ile Trp Ile 230 235 240	836
40	aca gtt tta cag tgc aga gat tta agt tgg ccc tct agt tat gga gac Thr Val Leu Gln Cys Arg Asp Leu Ser Trp Pro Ser Ser Tyr Gly Asp 245 250 255	884
	act cct act gtt tct ata aaa gga ata ctt aca ttg ccc aaa cca gtg Thr Pro Thr Val Ser Ile Lys Gly Ile Leu Thr Leu Pro Lys Pro Val 260 265 270	932
45	cat ttc aaa tct tca gcc aag gaa ggt tcc aac gct att gaa ttt atg His Phe Lys Ser Ser Ala Lys Glu Gly Ser Asn Ala Ile Glu Phe Met 275 280 285 290	980
50	gaa acg ttt gta ttt gct att aaa ctt caa aat cta caa act gta aga Glu Thr Phe Val Phe Ala Ile Lys Leu Gln Asn Leu Gln Thr Val Arg 295 300 305	1028

	ctt gta ttt aag att caa acc cag act ccc agg aag aaa acc att gga Leu Val Phe Lys Ile Gln Thr Gln Thr Pro Arg Lys Lys Thr Ile Gly 310 315 320	1076
5	gaa tgc tca atg tca ctc aga acc ctt agc aca cag gaa atg gat tac Glu Cys Ser Met Ser Leu Arg Thr Leu Ser Thr Gln Glu Met Asp Tyr 325 330 335	1124
10	tct ttg gat ata aca cca cct tca aaa att tct gtt tgc cat gca gaa Ser Leu Asp Ile Thr Pro Pro Ser Lys Ile Ser Val Cys His Ala Glu 340 345 350	1172
15	ctt gaa ttg ggg act tgt ttt caa gca gta aat agc aga att cag tta Leu Glu Leu Gly Thr Cys Phe Gln Ala Val Asn Ser Arg Ile Gln Leu 355 360 365 370	1220
20	caa att ctt gag gca cgg tac ctt cca agc tca tca aca cct ctg act Gln Ile Leu Glu Ala Arg Tyr Leu Pro Ser Ser Ser Thr Pro Leu Thr 375 380 385	1268
	ttg agt ttt ttc gtg aag gtg gga atg ttt agc tcg gga gag ttg att Leu Ser Phe Phe Val Lys Val Gly Met Phe Ser Ser Gly Glu Leu Ile 390 395 400	1316
25	tat aag aaa aag aca cgc tta ctg aag gcc tcc aat gga aga gtc aag Tyr Lys Lys Lys Thr Arg Leu Leu Lys Ala Ser Asn Gly Arg Val Lys 405 410 415	1364
30	tgg gga gag act atg att ttt cca ctt ata cag agt gaa aaa gaa att Trp Gly Glu Thr Met Ile Phe Pro Leu Ile Gln Ser Glu Lys Glu Ile 420 425 430	1412
35	gtt ttt ctc att aag ctt tac agt cga agc tct gta aga aga aaa cac Val Phe Leu Ile Lys Leu Tyr Ser Arg Ser Ser Val Arg Arg Lys His 435 440 445 450	1460
40	ttt gtg ggc cag att tgg ata agt gaa gac agt aat aac att gaa gca Phe Val Gly Gln Ile Trp Ile Ser Glu Asp Ser Asn Asn Ile Glu Ala 455 460 465	1508
	gtg aac cag tgg aaa gag aca gta ata aat cca gaa aag gtt gtt atc Val Asn Gln Trp Lys Glu Thr Val Ile Asn Pro Glu Lys Val Val Ile 470 475 480	1556
45	agg tgg cac aaa tta aat cca tct tga agacttcaca cattaatttg Arg Trp His Lys Leu Asn Pro Ser 485 490	1603
50	ggtgaagaac ttgacattct tttagaagac ttatgatttc aatttgctac caatgagaag aggcaaatca accaaatttg tcaatttatg ggggctataa ttatgggtata taatgtatct	1663 1723

gatagaaaat ttgataagaa aatgtaatga attttatcag atatccaaag taaaggaaat. 1783
 gttttaaaac tgcaacaaga gacacagaca gtaaaatcaa agtattatta ggatgactaa 1843
 5 ataaattata aagtctgtga ga 1865

<210> 2
 <211> 490
 10 <212> PRT
 <213> Homo sapiens
 <400> 2

15 Met Ala Thr Glu Phe Ile Lys Ser Cys Cys Gly Gly Cys Phe Tyr Gly
 1 5 10 15
 Glu Thr Glu Lys His Asn Phe Ser Val Glu Arg Asp Phe Lys Ala Ala
 20 20 25 30
 Val Pro Asn Ser Gln Asn Ala Thr Ile Ser Val Pro Pro Leu Thr Ser
 35 40 45
 Val Ser Val Lys Pro Gln Leu Gly Cys Thr Glu Asp Tyr Leu Leu Ser
 25 50 55 60
 Lys Leu Pro Ser Asp Gly Lys Glu Val Pro Phe Val Val Pro Lys Phe
 65 70 75 80
 30 Lys Leu Ser Tyr Ile Gln Pro Arg Thr Gln Glu Thr Pro Ser His Leu
 85 90 95
 Glu Glu Leu Glu Gly Ser Ala Arg Ala Ser Phe Gly Asp Arg Lys Val
 100 105 110
 35 Glu Leu Ser Ser Ser Ser Gln His Gly Pro Ser Tyr Asp Val Tyr Asn
 115 120 125
 Pro Phe Tyr Met Tyr Gln His Ile Ser Pro Asp Leu Ser Arg Arg Phe
 40 130 135 140
 Pro Pro Arg Ser Glu Val Thr Arg Leu Tyr Gly Ser Val Cys Asp Leu
 145 150 155 160
 45 Arg Thr Asn Lys Leu Pro Gly Ser Pro Gly Leu Ser Lys Ser Met Phe
 165 170 175
 Asp Leu Thr Asn Ser Ser Gln Arg Phe Ile Gln Arg His Asp Ser Leu
 180 185 190
 50

Ser Ser Val Pro Ser Ser Ser Ser Ser Arg Lys Asn Ser Gln Gly Ser
 195 200 205

5 Asn Arg Ser Leu Asp Thr Ile Thr Leu Ser Gly Asp Glu Arg Asp Phe
 210 215 220

Gly Arg Leu Asn Val Lys Leu Phe Tyr Asn Ser Ser Val Glu Gln Ile
 225 230 235 240

10 Trp Ile Thr Val Leu Gln Cys Arg Asp Leu Ser Trp Pro Ser Ser Tyr
 245 250 255

Gly Asp Thr Pro Thr Val Ser Ile Lys Gly Ile Leu Thr Leu Pro Lys
 260 265 270

15 Pro Val His Phe Lys Ser Ser Ala Lys Glu Gly Ser Asn Ala Ile Glu
 275 280 285

20 Phe Met Glu Thr Phe Val Phe Ala Ile Lys Leu Gln Asn Leu Gln Thr
 290 295 300

Val Arg Leu Val Phe Lys Ile Gln Thr Gln Thr Pro Arg Lys Lys Thr
 305 310 315 320

25 Ile Gly Glu Cys Ser Met Ser Leu Arg Thr Leu Ser Thr Gln Glu Met
 325 330 335

Asp Tyr Ser Leu Asp Ile Thr Pro Pro Ser Lys Ile Ser Val Cys His
 340 345 350

30 Ala Glu Leu Glu Leu Gly Thr Cys Phe Gln Ala Val Asn Ser Arg Ile
 355 360 365

Gln Leu Gln Ile Leu Glu Ala Arg Tyr Leu Pro Ser Ser Ser Thr Pro
 370 375 380

Leu Thr Leu Ser Phe Phe Val Lys Val Gly Met Phe Ser Ser Gly Glu
 385 390 395 400

40 Leu Ile Tyr Lys Lys Lys Thr Arg Leu Leu Lys Ala Ser Asn Gly Arg
 405 410 415

Val Lys Trp Gly Glu Thr Met Ile Phe Pro Leu Ile Gln Ser Glu Lys
 420 425 430

45 Glu Ile Val Phe Leu Ile Lys Leu Tyr Ser Arg Ser Ser Val Arg Arg
 435 440 445

50 Lys His Phe Val Gly Gln Ile Trp Ile Ser Glu Asp Ser Asn Asn Ile
 450 455 460

Glu Ala Val Asn Gln Trp Lys Glu Thr Val Ile Asn Pro Glu Lys Val
465 470 475 480

Val Ile Arg Trp His Lys Leu Asn Pro Ser
485 490

CLAIMS

- 5 1. An isolated polypeptide comprising
- (i) the amino acid sequence of SEQ ID NO: 2;
 - (ii) a variant thereof having substantially similar function selected from immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity; or
 - 10 (iii) a fragment of (i) or (ii) which retains substantially similar function selected from immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity.
2. A variant or fragment of the polypeptide defined by the amino acid sequence set
15 forth in SEQ. ID. No. 2 suitable for raising specific antibodies for said polypeptide and/or a naturally-occurring variant thereof.
3. A polynucleotide encoding a polypeptide as claimed in claim 1 or 2.
- 20 4. A polynucleotide as claimed in claim 3 which is a cDNA.
5. A polynucleotide encoding a polypeptide as claimed in claim 1, which polynucleotide comprises:
- 25 (a) the nucleic acid sequence of SEQ ID NO: 1 or the coding sequence thereof and/or a sequence complementary thereto;
 - (b) a sequence which hybridises to a sequence as defined in (a);
 - (c) a sequence that is degenerate as a result of the genetic code to a sequence as defined in (a) or (b); or
 - 30 (d) a sequence having at least 60% identity to a sequence as defined in (a), (b) or (c).

6. An expression vector comprising a polynucleotide sequence as claimed in any one of claims 3 to 5, which is capable of expressing a polypeptide according to claim 1 or 2.
- 5 7. A host cell containing an expression vector according to claim 6.
8. An antibody specific for a polypeptide as claimed in claim 1 or claim 2.
9. An isolated polynucleotide which directs expression *in vivo* of a polypeptide as
10 claimed in claim 1.
10. A polypeptide as claimed in claim 1 or a polynucleotide as claimed in claim 9 for use in therapeutic treatment of a human or non-human animal.
- 15 11. A pharmaceutical composition comprising a polypeptide as claimed in claim 1 or a polynucleotide as claimed in claim 9 and a pharmaceutically acceptable carrier or diluent.
12. Use of a polypeptide as claimed in claim 1 or a polynucleotide as claimed in
20 claim 9 in the preparation of medicament for use in therapy as an anti-viral, anti-tumour or immunomodulatory agent.
13. A method of treating a patient having a Type 1 interferon treatable disease, which
25 comprises administering to said patient an effective amount of a polypeptide as claimed in claim 1 or a polynucleotide as claimed in claim 9.
14. A method of producing a polypeptide according to claim 1 or 2, which method
comprises culturing host cells as claimed in claim 7 under conditions suitable for
obtaining expression of the polypeptide and isolating the said polypeptide.
30
15. A method of identifying a compound having immunomodulatory activity and/or
anti-viral activity and/or anti-tumour activity comprising providing a cell capable

of expressing the polypeptide of SEQ. ID. No. 2 or a naturally-occurring variant thereof, incubating said cell with a compound under test and monitoring for upregulation of the gene encoding said polypeptide or variant.

- 5 16. A polynucleotide capable of expressing *in vivo* an antisense sequence to a coding sequence for the amino acid sequence defined by SEQ. ID. No.2 or a naturally-occurring variant of said coding sequence for use in therapeutic treatment of a human or non-human animal.
- 10 17. An antibody as claimed in claim 8 for use in therapeutic treatment.
18. A set of primers for nucleic acid amplification which target sequences within a cDNA as claimed in claim 4.
- 15 19. A nucleic acid probe derived from a polynucleotide as claimed in any one of claims 3 to 5.
20. A probe as claimed in claim 19 which is attached to a solid support.
- 20 21. A method of predicting responsiveness of a patient to treatment with a Type 1 interferon, which comprises determining the level of the protein defined by the amino acid sequence set forth in SEQ. ID. No. 2 or a naturally-occurring variant thereof, or the corresponding mRNA, in a cell sample from said patient, wherein said sample is obtained from said patient following administration of a Type 1
25 interferon or is treated prior to said determining with a Type 1 interferon *in vitro*.
22. A method as claimed in claim 21 wherein the interferon administered prior to obtaining said sample or used to treat said sample *in vitro* is the interferon proposed for treatment of said patient.

23. A method as claimed in claim 21 or claim 22 wherein a sample comprising peripheral blood mononuclear cells isolated from a blood sample of the patient is treated with a Type 1 interferon *in vitro*.
- 5 24. A method as claimed in any one of claims 21 to 23 wherein said determining comprises determining the level of mRNA encoding the protein defined by the sequence set forth in SEQ. ID. No. 2 or a naturally-occurring variant of said protein.
- 10 25. A non-human transgenic animal capable of expressing a polypeptide that is claimed in claim 1.

ABSTRACTINTERFERON- α INDUCED GENE

5 The present invention relates to identification of a gene upregulated by
interferon- α administration corresponding to the cDNA sequence set forth in SEQ. ID.
No. 1. Determination of expression products of this gene is proposed as having utility in
predicting responsiveness to treatment with interferon- α and other interferons which act
at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same
10 gene is also envisaged.